Clinical Trial

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

Study acronym: SARA RCT
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-12-10; most recent amendment 2025-10-30.
Status change: Not Yet Recruiting → Recruiting 2025-10-30
Trial Details
NCT Number NCT06732596
Lead Sponsor Boston Medical Center
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Opioid Use Disorder
Enrollment 100 participants
Start Date 2025-10-30
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-03